Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ARX
ARX logo

ARX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Accelerant Holdings (ARX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
13.130
1 Day change
1.86%
52 Week Range
31.180
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Accelerant Holdings (ARX) does not present a strong buy opportunity for a beginner investor with a long-term focus at this time. The stock is currently experiencing a downward trend with no significant positive catalysts or strong trading signals to suggest immediate upside potential. Given the lack of recent news, neutral trading sentiment, and absence of clear financial performance data, it is prudent to hold off on investing in ARX until more favorable conditions emerge.

Technical Analysis

The MACD histogram is negative (-0.291) and contracting, indicating bearish momentum. RSI is at 25.17, suggesting the stock is nearing oversold territory but does not yet provide a clear buy signal. Moving averages are converging, showing indecision in price direction. Key support is at 12.672, and resistance is at 13.724, with the stock trading below the pivot point.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
4

Positive Catalysts

  • Analysts have raised price targets recently, with some maintaining Outperform ratings, citing the company's positioning in the SME insurance market and potential resilience against pricing pressures.

Neutral/Negative Catalysts

  • The stock has shown a consistent downward trend in the short term, with a -0.99% regular market change and a -1.92% post-market change. Technical indicators do not suggest a reversal, and trading sentiment from hedge funds and insiders remains neutral. Additionally, no recent news or significant events are driving positive momentum.

Financial Performance

No financial performance data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts generally maintain positive ratings, with several Outperform and Overweight recommendations. Price targets have been raised by firms like BMO Capital, Raymond James, and Piper Sandler, but some analysts have also lowered targets due to broader industry concerns and pricing challenges.

Wall Street analysts forecast ARX stock price to rise
9 Analyst Rating
Wall Street analysts forecast ARX stock price to rise
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 12.890
sliders
Low
17
Averages
19.62
High
24.48
Current: 12.890
sliders
Low
17
Averages
19.62
High
24.48
BMO Capital
Outperform
maintain
$17
AI Analysis
2026-06-16
Reason
BMO Capital
Price Target
$17
AI Analysis
2026-06-16
maintain
Outperform
Reason
BMO Capital raised the firm's price target on Accelerant to $17 from $16.50 and keeps an Outperform rating on the shares after hosting investor meetings with its management team. The firm believes that the stock can re-rate from current 14-x earnings multiple if it executes on guidance and evidences its business model is less exposed to softening insurance pricing cycle, the analyst tells investors in a research note.
Raymond James
NULL
to
Outperform
maintain
$16 -> $19
2026-06-01
Reason
Raymond James
Price Target
$16 -> $19
2026-06-01
maintain
NULL
to
Outperform
Reason
Raymond James raised the firm's price target on Accelerant to $19 from $16 and keeps an Outperform rating on the shares. The company's positioning in the specialty SME insurance market is viewed favorably, as it should remain relatively insulated from the aggressive pricing pressure that typically affects larger account business, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ARX
Unlock Now

People Also Watch